MGWM
ALNY icon

Marks Group Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Marks Group Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$818K Buy
2,717
+1,067
+65% +$322K 0.07% 220
2026
Q1 		$546K Buy
+1,650
New +$561K 0.05% 236

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marks Group Wealth Management's ALNY Position: Q2 2026 in Review

Marks Group Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 65% in Q2 2026, buying an estimated $322K and bringing the position to 2,717 shares worth $818K. The position accounts for 0.07% of the portfolio, ranked #220.

Marks Group Wealth Management first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Marks Group Wealth Management held 2,717 shares of Alnylam Pharmaceuticals worth $818K as of Q2 2026.
  • Marks Group Wealth Management bought 1,067 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $322K.
  • Alnylam Pharmaceuticals made up 0.07% of Marks Group Wealth Management's portfolio in Q2 2026, its #220 holding.
  • Marks Group Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.